Comparative Pharmacology
Head-to-head clinical analysis: JESDUVROQ versus LUSEDRA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: JESDUVROQ versus LUSEDRA.
JESDUVROQ vs LUSEDRA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
JESDUVROQ is a small molecule inhibitor of cyclin-dependent kinase 4 (CDK4) and CDK6, blocking retinoblastoma protein phosphorylation and inducing G1 cell cycle arrest.
LUSEDRA (valbenazine) is a selective vesicular monoamine transporter 2 (VMAT2) inhibitor. It reduces presynaptic dopamine release by inhibiting VMAT2, thereby reducing dopamine neurotransmission in the striatum.
IV: 10 mg/kg every 4 weeks, infused over 60 minutes.
5 mg orally once daily.
None Documented
None Documented
Terminal elimination half-life is 12-15 hours in patients with normal renal function (CrCl >90 mL/min). Half-life increases with renal impairment (up to >30 hours in end-stage renal disease), requiring dose adjustment.
8-12 hours (terminal, prolonged in renal impairment; dose adjustment needed if CrCl <30 mL/min).
Primarily renal elimination (70-80% unchanged drug) via glomerular filtration and active tubular secretion; biliary/fecal excretion accounts for 15-20% as metabolites, with less than 5% unchanged in feces.
Primarily renal (70-80% as unchanged drug); 20-30% via biliary/fecal.
Category C
Category C
Anticholinergic
Anticholinergic